{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:16:44Z","timestamp":1786119404298,"version":"build-2736575974"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"28","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1097\/md.0000000000004167","type":"journal-article","created":{"date-parts":[[2016,7,14]],"date-time":"2016-07-14T10:54:44Z","timestamp":1468493684000},"page":"e4167","source":"Crossref","is-referenced-by-count":8,"title":["Renoprotective effects of renin\u2013angiotensin system inhibitor combined with calcium channel blocker or diuretic in hypertensive patients"],"prefix":"10.1097","volume":"95","author":[{"given":"Yiming","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongshuang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sehee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuliang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-32-20210226","doi-asserted-by":"crossref","first-page":"241S","DOI":"10.1093\/ajh\/6.7.241S","article-title":"Pathophysiology of hypertensive renal damage","volume":"6","author":"Ritz","year":"1993","journal-title":"Am J Hypertens"},{"key":"R2-32-20210226","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/hr.2014.20","article-title":"The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014)","volume":"37","author":"Shimamoto","year":"2014","journal-title":"Hypertens Res"},{"key":"R3-32-20210226","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1093\/eurheartj\/eht151","article-title":"2013 ESH\/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"34","author":"Mancia","year":"2013","journal-title":"Eur Heart J"},{"key":"R4-32-20210226","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"key":"R5-32-20210226","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/0002-8703(84)90763-4","article-title":"The prognostic significance of proteinuria: the Framingham study","volume":"108","author":"Kannel","year":"1984","journal-title":"Am Heart J"},{"key":"R6-32-20210226","first-page":"S10","article-title":"Proteinuria is a risk factor for mortality over 10 years of follow-up. MRFIT Research Group. Multiple Risk Factor Intervention Trial","volume":"63","author":"Grimm","year":"1997","journal-title":"Kidney Int Suppl"},{"key":"R7-32-20210226","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(04)16980-8","article-title":"Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial","volume":"364","author":"Poole-Wilson","year":"2004","journal-title":"Lancet"},{"key":"R8-32-20210226","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1586\/14779072.2015.986464","article-title":"Azelnidipine and glucose tolerance: possible indications and treatment selection for hypertensive patients with metabolic disorders","volume":"13","author":"Shimada","year":"2015","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"R9-32-20210226","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1055\/s-0035-1565180","article-title":"Nifedipine treatment for hypertension is associated with enhanced lipolytic activity and accelerated clearance of postprandial lipemia","volume":"48","author":"Grosskopf","year":"2016","journal-title":"Horm Metab Res"},{"key":"R11-32-20210226","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1159\/000181670","article-title":"Comparative effects of ticrynafen and hydrochlorothiazide on blood pressure, renal function, serum uric acid and electrolytes, and body fluid spaces in hypertensive man","volume":"23","author":"Bauer","year":"1979","journal-title":"Nephron"},{"key":"R12-32-20210226","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/jhh.2010.104","article-title":"Olmesartan\/amlodipine vs olmesartan\/hydrochlorothiazide in hypertensive patients with metabolic syndrome: the OLAS study","volume":"25","author":"Martinez-Martin","year":"2011","journal-title":"J Hum Hypertens"},{"key":"R13-32-20210226","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1016\/j.clinthera.2012.06.014","article-title":"Comparison of the efficacy and safety profiles of two fixed-dose combinations of antihypertensive agents, amlodipine\/benazepril versus valsartan\/hydrochlorothiazide, in patients with type 2 diabetes mellitus and hypertension: a 16-week, multicenter, randomized, double-blind, noninferiority Study","volume":"34","author":"Lee","year":"2012","journal-title":"Clin Ther"},{"key":"R14-32-20210226","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1093\/ndt\/gft034","article-title":"Kidney-protective effects of azelnidipine versus a diuretic in combination with olmesartan in hypertensive patients with diabetes and albuminuria: a randomized study","volume":"28","author":"Kojima","year":"2013","journal-title":"Nephrol Dial Transpl"},{"key":"R15-32-20210226","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/hr.2010.233","article-title":"Comparison of combination therapies, including the angiotensin receptor blocker olmesartan and either a calcium channel blocker or a thiazide diuretic, in elderly patients with hypertension","volume":"34","author":"Kato","year":"2011","journal-title":"Hypertens Res"},{"key":"R16-32-20210226","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.amjhyper.2007.05.012","article-title":"Addition of manidipine improves the antiproteinuric effect of candesartan in hypertensive patients with type II diabetes and microalbuminuria","volume":"20","author":"Fogari","year":"2007","journal-title":"Am J Hypertens"},{"key":"R17-32-20210226","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/sj.jhh.1001279","article-title":"Effect of two antihypertensive combinations on metabolic control in type-2 diabetic hypertensive patients with albuminuria: a randomised, double-blind study","volume":"15","author":"Fern\u00e1ndez","year":"2001","journal-title":"J Hum Hypertens"},{"key":"R18-32-20210226","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/MAJ.0b013e3181d658c4","article-title":"Combination therapy of calcium channel blocker and angiotensin II receptor blocker reduces augmentation index in hypertensive patients","volume":"339","author":"Doi","year":"2010","journal-title":"Am J Med Sci"},{"key":"R19-32-20210226","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0140-6736(09)62100-0","article-title":"Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial","volume":"375","author":"Bakris","year":"2010","journal-title":"Lancet"},{"key":"R20-32-20210226","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3109\/10641963.2013.810227","article-title":"Angiotensin receptor blocker (ARB)-diuretic versus ARB-calcium channel blocker combination therapy for hypertension uncontrolled by ARB monotherapy","volume":"36","author":"Oshikawa","year":"2014","journal-title":"Clin Exp Hypertens"},{"key":"R21-32-20210226","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1097\/HJH.0000000000000281","article-title":"Combinations of olmesartan and a calciumchannel blocker or a diuretic inelderly hypertensive patients: a randomized, controlled trial","volume":"32","author":"Ogihara","year":"2014","journal-title":"J Hypertens"},{"key":"R22-32-20210226","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s12325-009-0015-8","article-title":"Fixed-dose manidipine\/delapril versus losartan\/hydrochlorothiazide in hypertensive patients with type 2 diabetes and microalbuminuria","volume":"26","author":"Kohlmann","year":"2009","journal-title":"Adv Ther"},{"key":"R23-32-20210226","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000205521","article-title":"Add-on benefits of amlodipine and thiazide in nondiabetic chronic kidney disease stage 1\/2 patients treated with valsartan","volume":"32","author":"Kaneshiro","year":"2009","journal-title":"Kidney Blood Press Res"},{"key":"R24-32-20210226","doi-asserted-by":"crossref","first-page":"366","DOI":"10.3109\/10641963.2010.503299","article-title":"Combination of angiotensin II receptor antagonist with calcium channel blocker or diuretic as antihypertensive therapy for patients with chronic kidney disease","volume":"33","author":"Ishimitsu","year":"2011","journal-title":"Clin Exp Hypertens"},{"key":"R25-32-20210226","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/ki.2008.102","article-title":"Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study","volume":"73","author":"Bakris","year":"2008","journal-title":"Kidney Int"},{"key":"R26-32-20210226","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1161\/01.CIR.0000031732.78052.81","article-title":"Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population","volume":"106","author":"Hillege","year":"2002","journal-title":"Circulation"},{"key":"R27-32-20210226","first-page":"491","article-title":"Serum creatinine level and eGFR as the indices of renal function in present-day clinical practice","volume":"67","author":"Kuc","year":"2010","journal-title":"Przegl Lek"},{"key":"R28-32-20210226","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1681\/ASN.2008121270","article-title":"Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes","volume":"20","author":"Ninomiya","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"R29-32-20210226","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"62","author":"Liberati","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"R30-32-20210226","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"R32-32-20210226","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1037\/1082-989X.11.2.193","article-title":"Assessing heterogeneity in meta-analysis: Q statistic or I2 index?","volume":"11","author":"Huedo-Medina","year":"2006","journal-title":"Psychol Methods"},{"key":"R33-32-20210226","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"R34-32-20210226","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1471-2288-14-30","article-title":"Which is more generalizable, powerful and interpretable in meta-analyses, mean difference or standardized mean difference?","volume":"14","author":"Takeshima","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"R35-32-20210226","first-page":"64","article-title":"Serum creatinine and creatinine clearance to estimate renal function in essential hypertension","volume":"26","author":"Jabary","year":"2006","journal-title":"Nefrologia"},{"key":"R36-32-20210226","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1093\/qjmed\/hcn032","article-title":"Comparison of combined urea and creatinine clearance and prediction equations as measures of residual renal function when GFR is low","volume":"101","author":"Almond","year":"2008","journal-title":"QJM"},{"key":"R37-32-20210226","first-page":"686","article-title":"24-hour creatinine clearance reliability for estimation of glomerular filtration rate in different stages of chronic kidney disease","volume":"21","author":"El-Minshawy","year":"2010","journal-title":"Saudi J Kidney Dis Transplant"},{"key":"R38-32-20210226","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1590\/0102-311X00150814","article-title":"Comparison of serum creatinine levels in different color\/race categories in a Brazilian population","volume":"31","author":"Barcellos","year":"2015","journal-title":"Cad Saude Publica"},{"key":"R39-32-20210226","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/1471-2369-15-165","article-title":"Urinary albumin excretion and prevalence of microalbuminuria in a general Chinese population: a cross-sectional study","volume":"15","author":"Yan","year":"2014","journal-title":"BMC Nephrol"},{"key":"R40-32-20210226","first-page":"23","article-title":"Microalbuminuria: prevalence in hypertensives and diabetics","volume":"31","author":"Col","year":"2004","journal-title":"Acta Med Aust"},{"key":"R41-32-20210226","doi-asserted-by":"crossref","first-page":"754","DOI":"10.7326\/0003-4819-123-10-199511150-00003","article-title":"Blood pressure control, proteinuria, and the progression of renal disease. The modification of diet in renal disease study","volume":"123","author":"Peterson","year":"1995","journal-title":"Ann Intern Med"},{"key":"R42-32-20210226","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.semnephrol.2005.03.001","article-title":"Pathologic basis and treatment considerations in chronic kidney disease-related hypertension","volume":"25","author":"Sica","year":"2005","journal-title":"Semin Nephrol"},{"key":"R43-32-20210226","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.amjmed.2012.04.008","article-title":"Hypertension and chronic kidney disease progression: why the suboptimal outcomes?","volume":"125","author":"Bidani","year":"2012","journal-title":"Am J Med"},{"key":"R44-32-20210226","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1136\/bmj.294.6585.1443","article-title":"Effect of antihypertensive treatment on kidney function in diabetic nephropathy","volume":"294","author":"Parving","year":"1987","journal-title":"Br Med J"},{"key":"R45-32-20210226","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","article-title":"The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report","volume":"289","author":"Chobanian","year":"2003","journal-title":"JAMA"},{"key":"R46-32-20210226","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/08037050701461084","article-title":"2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"16","author":"Mansia","year":"2007","journal-title":"Blood Press"},{"key":"R47-32-20210226","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/hr.2009.34","article-title":"The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009)","volume":"32","author":"Ogihara","year":"2009","journal-title":"Hypertens Res"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000004167","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:10:27Z","timestamp":1786039827000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00005792-201607120-00032"}},"subtitle":["A PRISMA-compliant meta-analysis"],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":45,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000004167","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]}}}